GET DAILY SIGNALSAktis Oncology (AKTS) Posts Q3 Miss as R&D Costs Climb Sharply
Key Takeaways
- Aktis Oncology reported third-quarter fiscal 2026 results on November 12, 2026, for the quarter ended September 30, 2026, missing consensus estimates on both revenue and EPS.
- Collaboration revenue reached $3.9 million, up 147% from $1.6 million a year earlier, but fell short of the roughly $4.1 million consensus forecast.
- Non-GAAP EPS came in at -$0.54, versus a consensus estimate of -$0.49, a $0.05 shortfall driven by sharply higher operating expenses.
- Net loss widened to $29.9 million from $15.5 million a year earlier, as R&D spending surged 95% to $32.1 million.
- Cash, cash equivalents, and marketable securities totaled $492.9 million, which management expects to fund the operating plan into 2029.
Earnings Context and Why It Matters
Aktis Oncology, a clinical-stage radiopharmaceutical company, completed its IPO in January 2026 and is now advancing a pipeline of targeted radiopharmaceuticals. Because the company is pre-revenue outside of collaboration income, investors focus less on the income statement than on three signals: the pace of its Eli Lilly research collaboration, the rate of cash burn, and clinical trial progress. This quarter matters because it is the first full reporting period since the company's public listing and because rising R&D costs directly shape how far the current cash runway extends, while upcoming trial readouts determine the long-term investment case. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the quarter ended September 30, 2026, Aktis Oncology reported collaboration revenue of $3.9 million, up from $1.6 million in the prior-year period, reflecting continued advancement of its research collaboration with Eli Lilly and Company. The figure nonetheless came in below the roughly $4.1 million consensus estimate, a shortfall of about 4.7%. Revenue is recognized over time using the cost incurred input method.
On the bottom line, the company posted a net loss of $29.9 million, widening from $15.5 million a year earlier, and a basic and diluted loss per share of $0.54, compared with $19.18 in the prior-year quarter. Non-GAAP EPS of -$0.54 missed the consensus estimate of -$0.49 by $0.05. The wider loss was driven by higher operating expenses, partially offset by increased collaboration revenue and interest income.
Research and development expenses climbed 95% to $32.1 million, reflecting advancement of the AKY-1189 and AKY-2519 clinical trials and higher headcount in clinical development and manufacturing. G&A expenses rose to $6.5 million from $3.3 million, tied to public-company costs and growth. For the first nine months of fiscal 2026, collaboration revenue was $10.5 million and net loss was $72.4 million.
Cash, cash equivalents, and marketable securities stood at $492.9 million as of September 30, 2026, up from $226.8 million at December 31, 2025, primarily reflecting IPO proceeds. Management expects this balance to fund operations into 2029.
Market Reaction and Investor Sentiment
Aktis Oncology shares traded modestly lower in the session following the release, with the stock down roughly 2.5% intraday, according to market data. The reaction reflects a straightforward interpretation: a revenue and EPS miss, paired with a near-doubling of operating expenses, weighed on sentiment even though the balance sheet remains strong. Investors are balancing two competing narratives. The first is a near $493 million cash position that removes near-term funding risk. The second is a widening loss as the company scales multiple clinical trials, a pattern typical of clinical-stage biopharmaceutical companies but one that requires investors to look past the quarterly miss toward the upcoming data catalysts.
Forward Outlook and Key Factors to Monitor
Looking ahead, the investment narrative for Aktis Oncology will be defined by clinical data rather than quarterly revenue. The company recently initiated a third Phase 1b trial, BActinium-2, evaluating AKY-2519 in non-small cell lung cancer and other tumors expressing the B7-H3 protein target. This expands the company's U.S. footprint across two distinct targets: Nectin-4, addressed by AKY-1189, and B7-H3, addressed by AKY-2519.
The most important near-term catalyst is preliminary data from the NECTINIUM-2 trial of AKY-1189, expected in the first quarter of 2027, followed by initial AKY-2519 results later in 2027. These readouts will be closely watched because they provide the first meaningful clinical validation of the company's radiopharmaceutical platform.
On the financial side, investors should monitor the trajectory of R&D and G&A spending as additional trials enroll patients. While the $492.9 million cash balance supports operations into 2029, consensus forecasts suggest collaboration revenue may moderate in 2027, meaning losses are likely to remain wide. The company's hybrid manufacturing strategy, including its GMP facility in Boston, is another factor to watch as it positions for later-stage supply.
As with any early-stage biotech, the key risks include clinical setbacks, regulatory hurdles, and execution challenges in scaling manufacturing, all of which could meaningfully affect the outlook.
Using AI Tools for Biotech Analysis
In my view, tools like Tickeron’s AI Screener help cut through the noise when evaluating clinical-stage names. I ran a quick scan on comparable radiopharma and oncology peers to cross-check momentum and volatility metrics, which gave useful context around how Aktis Oncology stacks up on technical signals and sector trends. It is one of several AI-driven resources I turn to when monitoring event-driven stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for AKTS turns positive, indicating new upward trend
AKTS saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 65 similar instances where the indicator turned positive. In 58 of the 65 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AKTS's RSI Indicator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for AKTS just turned positive on October 21, 2026. Looking at past instances where AKTS's MACD turned positive, the stock continued to rise in 25 of 31 cases over the following month. The odds of a continued upward trend are 81%.
Following a +10.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTS advanced for three days, in 172 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for AKTS moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AKTS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.815) is normal, around the industry mean (3.498). P/E Ratio (-11.965) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AKTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of filter products for radio frequency front-ends for mobile wireless devices
Industry Biotechnology
Advertisement